A 73-year-old man with porokeratosis palmaris, plantaris et disseminata is presented. He had punctate, guttate and annular hyperkeratotic papular lesions widespread on his body with thorn-like hyperkeratosis on the palms and soles. Lesional skin did not show mutations of TP53 exons 5–6, 7, 8.

Keywords:
Porokeratosis, TP53 gene
1.
Shaw JC, White CR: Porokeratosis plantaris, palmaris et disseminata. J Am Acad Dermatol 1984;11:454–460.
2.
Neumann RA, Knobler RM, Gebhart W: Unusual presentation of porokeratosis palmaris plantaris et disseminata. J Am Acad Dermatol 1989;21:1131–1133.
3.
Steger O, Schwab U, Braun-Falco O, Kind P, Plewig G: Porokeratosis plantaris, palmaris et disseminata. Hautarzt 1985;36:403–407.
4.
McCallister RE, Estes SA, Yarbrough CL: Porokeratosis plantaris, palmaris, et disseminata. Report of a case and treatment with isotretinoin. J Am Acad Dermatol 1985;13:598–603.
5.
Lestringant GG, Berge T: Porokeratosis punctata palmaris et plantaris. Arch Dermatol 1989;125:816–819.
6.
Chernosky ME: Porokeratosis. Arch Dermatol 1986;122:869–870.
7.
McNutt NS, Saenz-Santamaria C, Volkenandt M, Shea CR, Albino AP: Abnormalities of p53 protein expression in cutaneaus disorders. Arch Dermatol 1994;130:225–232.
8.
Otsuka F, Shima A, Ishibashi Y: Porokeratosis as a premalignant condition of the skin: Cytologic demonstration of abnormal DNA ploidy in cells of the epidermis. Cancer 1989;63:891–896.
9.
Puig L, Alegre M, Costa I, Matias-Guiu X: Overexpression of p53 in disseminated superficial actinic porokeratosis with and without malignant degeneration. Arch Dermatol 1995;131:353–354.
10.
Magee JW, McCalmont T, LeBoit PE: Overexpression of p53 tumor suppressor protein in porokeratosis. Arch Dermatol 1994;130:187–190.
11.
Kanitakis J, Misery L, Nicolas JF, Lyonnet S, Chouvet B, Haftek M, Faure M, Claudy A, Thivolet J: Disseminated superficial porokeratosis in a patient with AIDS. Br J Dermatol 1994;131:284–289.
12.
Nelson C, Cowper S, Morgan M: p53, mdm-2, and p21 waf-1 in the porokeratoses. Am J Dermatopathol 1999;21:420–425.
13.
Sasaki S, Urano Y, Nakagawa K, Nagae H, Nakanishi H, Arase S: Linear porokeratosis with multiple squamous cell carcinomas: Study of p53 expression in porokeratosis and squamous cell carcinoma. Br J Dermatol 1996;134:1151–1153.
14.
Urano Y, Sasaki S, Ninomiya Y, Oura H, Arase S: Immunohistochemical detection of p53 tumor suppressor protein in porokeratosis. J Dermatol 1996;23:365–368.
15.
Brodkin RH, Rickert RR, Fuller FW, Saporito C: Malignant disseminated porokeratosis. Arch Dermatol 1987;123:1521–1526.
16.
Patrizi A, Passarini B, Minghetti G, Masina M: Porokeratosis palmaris et plantaris disseminata: An unusual clinical presentation. J Am Acad Dermatol 1989;21:415–418.
17.
Marschalko M, Somlai B: Porokeratosis plantaris, palmaris et disseminata. Arch Dermatol 1986;122:890–891.
18.
McKusick VA: Mendelian Inheritance in Man: A Catalog of Human Genes and Genetic Disorders. Baltimore, Johns Hopkins University Press, 1994.
19.
Beers B, Jaszez W, Sheetz K, Hogan DJ, Lynch PJ: Porokeratosis palmaris et plantaris disseminata: Report of a case with abnormal DNA ploidy in lesional epidermis. Arch Dermatol 1992;128:236–239.
20.
Braun Falco O, Plewig G, Wolff HH, Winkelmann RK: Dermatology. Berlin, Springer, 1991.
21.
Lucker GPH, Steijlen PM: The coexistence of linear and giant porokeratosis associated with Bowen’s disease. Dermatology 1994;184:78–80.
22.
Bencini PL, Tarantino A, Grimalt R, Ponticelli C, Caputo R: Porokeratosis and immunosuppression. Br J Dermatol 1995;132:74–78.
23.
Ninomiya Y, Urano Y, Yoshimoto K, Iwahana H, Sasaki S, Arase S, Itakura M: p53 gene mutation analysis in porokeratosis and porokeratosis-associated squamous cell carcinoma. J Dermatol Sci 1997;14:173–178.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.